These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 31355705)
1. Glycyrrhizic acid-loaded pH-sensitive poly-(lactic-co-glycolic acid) nanoparticles for the amelioration of inflammatory bowel disease. Zeeshan M; Ali H; Khan S; Mukhtar M; Khan MI; Arshad M Nanomedicine (Lond); 2019 Aug; 14(15):1945-1969. PubMed ID: 31355705 [No Abstract] [Full Text] [Related]
2. Evaluating the mucoprotective effects of glycyrrhizic acid-loaded polymeric nanoparticles in a murine model of 5-fluorouracil-induced intestinal mucositis via suppression of inflammatory mediators and oxidative stress. Zeeshan M; Atiq A; Ain QU; Ali J; Khan S; Ali H Inflammopharmacology; 2021 Oct; 29(5):1539-1553. PubMed ID: 34420176 [TBL] [Abstract][Full Text] [Related]
3. Cell Line and Augument Cellular Uptake Study of Statistically Optimized Sustained Release Capecitabine Loaded Eudragit S100/PLGA(poly(lacticco- glycolic acid)) Nanoparticles for Colon Targeting. Pandey S; Vijayendra Swamy SM; Ubaid Ulla UM; Gupta A; Patel H; Yadav JS Curr Drug Deliv; 2017 Sep; 14(6):887-899. PubMed ID: 27538461 [TBL] [Abstract][Full Text] [Related]
4. Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases. Ali H; Weigmann B; Neurath MF; Collnot EM; Windbergs M; Lehr CM J Control Release; 2014 Jun; 183():167-77. PubMed ID: 24685705 [TBL] [Abstract][Full Text] [Related]
5. Dual Functional Eudragit Gao C; Yu S; Zhang X; Dang Y; Han DD; Liu X; Han J; Hui M Int J Nanomedicine; 2021; 16():1405-1422. PubMed ID: 33658780 [TBL] [Abstract][Full Text] [Related]
6. Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease. Leonard F; Srinivasan S; Liu X; Collnot EM; Ferrari M; Lehr CM; Godin B Eur J Pharm Biopharm; 2020 Jun; 151():61-72. PubMed ID: 32283213 [TBL] [Abstract][Full Text] [Related]
7. pH-sensitive nanoparticles for colonic delivery of curcumin in inflammatory bowel disease. Beloqui A; Coco R; Memvanga PB; Ucakar B; des Rieux A; Préat V Int J Pharm; 2014 Oct; 473(1-2):203-12. PubMed ID: 25014369 [TBL] [Abstract][Full Text] [Related]
8. Oral administration of pH-sensitive curcumin-loaded microparticles for ulcerative colitis therapy. Xiao B; Si X; Zhang M; Merlin D Colloids Surf B Biointerfaces; 2015 Nov; 135():379-385. PubMed ID: 26275840 [TBL] [Abstract][Full Text] [Related]
10. Colon-targeted delivery of cyclosporine A using dual-functional Eudragit Naeem M; Bae J; Oshi MA; Kim MS; Moon HR; Lee BL; Im E; Jung Y; Yoo JW Int J Nanomedicine; 2018; 13():1225-1240. PubMed ID: 29535519 [TBL] [Abstract][Full Text] [Related]
11. Ramulus mori polysaccharide-loaded PLGA nanoparticles and their anti-inflammatory effects in vivo. Feng Z; Peng S; Wu Z; Jiao L; Xu S; Wu Y; Liu Z; Hu Y; Liu J; Wu Y; Wang D Int J Biol Macromol; 2021 Jul; 182():2024-2036. PubMed ID: 34087293 [TBL] [Abstract][Full Text] [Related]
12. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440 [TBL] [Abstract][Full Text] [Related]
13. Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach for Colon-Targeted Oral Delivery of Berberine. Zhang L; Li M; Zhang G; Gao C; Wang S; Zhang T; Ma C; Wang L; Zhu Q Mol Pharm; 2021 Apr; 18(4):1573-1581. PubMed ID: 33629860 [TBL] [Abstract][Full Text] [Related]
14. Budesonide Loaded PLGA Nanoparticles for Targeting the Inflamed Intestinal Mucosa--Pharmaceutical Characterization and Fluorescence Imaging. Ali H; Weigmann B; Collnot EM; Khan SA; Windbergs M; Lehr CM Pharm Res; 2016 May; 33(5):1085-92. PubMed ID: 26718953 [TBL] [Abstract][Full Text] [Related]
15. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles. Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911 [TBL] [Abstract][Full Text] [Related]
16. pH-responsive Astragalus polysaccharides-loaded poly(lactic-co-glycolic acid) nanoparticles and their in vitro immunogenicity. Xu S; Wusiman A; Liu Z; Gu P; Ni H; Zhang Y; Hu Y; Liu J; Wu Y; Wang D Int J Biol Macromol; 2019 Mar; 125():865-875. PubMed ID: 30576729 [TBL] [Abstract][Full Text] [Related]
17. In vitro IFN-α release from IFN-α- and pegylated IFN-α-loaded poly(lactic-co-glycolic acid) and pegylated poly(lactic-co-glycolic acid) nanoparticles. Feczkó T; Fodor-Kardos A; Sivakumaran M; Haque Shubhra QT Nanomedicine (Lond); 2016 Aug; 11(16):2029-34. PubMed ID: 27462975 [TBL] [Abstract][Full Text] [Related]
18. Formulation and in vitro characterization of Eudragit® L100 and Eudragit® L100-PLGA nanoparticles containing diclofenac sodium. Cetin M; Atila A; Kadioglu Y AAPS PharmSciTech; 2010 Sep; 11(3):1250-6. PubMed ID: 20697984 [TBL] [Abstract][Full Text] [Related]
19. Targeting Inflammatory Lesions Facilitated by Galactosylation Modified Delivery System Eudragit/Gal-PLGA@Honokiol for the treatment of Ulcerative Colitis. Wang A; Liu Y; Xiong W; Li W; Li J; Yang Z; Zou Z; Luo Y; Chen Z; Li H; Vong CT; Zou L J Pharm Sci; 2024 Sep; 113(9):2744-2755. PubMed ID: 38901529 [TBL] [Abstract][Full Text] [Related]
20. Drug delivery to inflamed colon by nanoparticles: comparison of different strategies. Coco R; Plapied L; Pourcelle V; Jérôme C; Brayden DJ; Schneider YJ; Préat V Int J Pharm; 2013 Jan; 440(1):3-12. PubMed ID: 22820482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]